Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 76

1.

Mir-194 is a hepatocyte gate keeper hindering HCV entry through targeting CD81 receptor.

Mekky RY, El-Ekiaby NM, Hamza MT, Elemam NM, El-Sayed M, Esmat G, Abdelaziz AI.

J Infect. 2015 Jan;70(1):78-87. doi: 10.1016/j.jinf.2014.08.013. Epub 2014 Sep 9.

PMID:
25218426
2.

MicroRNA profile before and after antiviral therapy in liver transplant recipients for hepatitis C virus cirrhosis.

Gelley F, Zadori G, Nemes B, Fassan M, Lendvai G, Sarvary E, Doros A, Gerlei Z, Nagy P, Schaff Z, Kiss A.

J Gastroenterol Hepatol. 2014 Jan;29(1):121-7. doi: 10.1111/jgh.12362.

PMID:
24033414
3.

CLEC4M-positive and CD81-negative Huh7 cells are not susceptible to JFH-1 HCVcc infection but mediate transinfection.

Ishibashi M, Morita N, Nomura-Kawaguchi C, Shimizu Y, Wakita T, Esumi M.

Arch Virol. 2014 Nov;159(11):2949-55. doi: 10.1007/s00705-014-2150-z. Epub 2014 Jun 26.

PMID:
24965233
4.

MiR-122 decreases HCV entry into hepatocytes through binding to the 3' UTR of OCLN mRNA.

Sendi H, Mehrab-Mohseni M, Foureau DM, Ghosh S, Walling TL, Steuerwald N, Zamor PJ, Kaplan KJ, Jacobs C, Ahrens WA, Russo MW, Clemens MG, Schrum LW, Bonkovsky HL.

Liver Int. 2015 Apr;35(4):1315-23. doi: 10.1111/liv.12698. Epub 2014 Oct 28.

PMID:
25302477
5.

Contradicting roles of miR-182 in both NK cells and their host target hepatocytes in HCV.

El Sobky SA, El-Ekiaby NM, Mekky RY, Elemam NM, Mohey Eldin MA, El-Sayed M, Esmat G, Abdelaziz AI.

Immunol Lett. 2016 Jan;169:52-60. doi: 10.1016/j.imlet.2015.10.013. Epub 2015 Oct 27.

PMID:
26518141
6.

Active RNA replication of hepatitis C virus downregulates CD81 expression.

Ke PY, Chen SS.

PLoS One. 2013;8(1):e54866. doi: 10.1371/journal.pone.0054866. Epub 2013 Jan 22.

7.

Increased miR-16 expression induced by hepatitis C virus infection promotes liver fibrosis through downregulation of hepatocyte growth factor and Smad7.

Zhu B, Wei XX, Wang TB, Zhou YC, Liu AM, Zhang GW.

Arch Virol. 2015 Aug;160(8):2043-50. doi: 10.1007/s00705-015-2474-3. Epub 2015 Jun 13.

PMID:
26071245
8.

Inhibition of HCV 3a genotype entry through host CD81 and HCV E2 antibodies.

Ashfaq UA, Qasim M, Yousaf MZ, Awan MT, Jahan S.

J Transl Med. 2011 Nov 10;9:194. doi: 10.1186/1479-5876-9-194.

9.

Generation of infectious HCV pseudo typed particles and its utilization for studying the role of CD81 & SRBI receptors in HCV infection.

Rafique S, Idrees M, Ali A, Sahibzada KI, Iqbal M.

Mol Biol Rep. 2014 Jun;41(6):3813-9. doi: 10.1007/s11033-014-3247-x. Epub 2014 Feb 19.

PMID:
24549717
10.

Significance of palmitoylation of CD81 on its association with tetraspanin-enriched microdomains and mediating hepatitis C virus cell entry.

Zhu YZ, Luo Y, Cao MM, Liu Y, Liu XQ, Wang W, Wu DG, Guan M, Xu QQ, Ren H, Zhao P, Qi ZT.

Virology. 2012 Aug 1;429(2):112-23. doi: 10.1016/j.virol.2012.03.002. Epub 2012 May 4.

11.

Impact of single nucleotide polymorphisms in the essential HCV entry factor CD81 on HCV infectivity and neutralization.

Deest M, Westhaus S, Steinmann E, Manns MP, von Hahn T, Ciesek S.

Antiviral Res. 2014 Jan;101:37-44. doi: 10.1016/j.antiviral.2013.10.018. Epub 2013 Nov 7.

PMID:
24211330
12.

Altered expression of the tetraspanin CD81 on B and T lymphocytes during HIV-1 infection.

Meroni L, Milazzo L, Menzaghi B, Mazzucchelli R, Mologni D, Morelli P, Broggini V, Adorni F, Galli M, Riva A.

Clin Exp Immunol. 2007 Jan;147(1):53-9.

13.

Comparison of envelope 2 CD81 binding regions in PBMC-derived versus serum-derived hepatitis C virus isolates: higher conservation of CD81 region 2 in PBMC isolates.

Welker MW, Welsch C, Ochs D, Hofmann WP, Herrmann E, Piiper A, Hartmann RW, Zeuzem S, Sarrazin C, Kronenberger B.

J Viral Hepat. 2011 Mar;18(3):181-92. doi: 10.1111/j.1365-2893.2010.01296.x.

PMID:
20367804
14.

Hepatitis C virus induces epidermal growth factor receptor activation via CD81 binding for viral internalization and entry.

Diao J, Pantua H, Ngu H, Komuves L, Diehl L, Schaefer G, Kapadia SB.

J Virol. 2012 Oct;86(20):10935-49. Epub 2012 Aug 1.

15.

Inhibition of microRNA-199a-5p reduces the replication of HCV via regulating the pro-survival pathway.

Wang H, Gao H, Duan S, Song X.

Virus Res. 2015 Oct 2;208:7-12. doi: 10.1016/j.virusres.2015.05.002. Epub 2015 May 29.

PMID:
26027911
16.

miR-215 Enhances HCV Replication by Targeting TRIM22 and Inactivating NF-κB Signaling.

Tian H, He Z.

Yonsei Med J. 2018 Jun;59(4):511-518. doi: 10.3349/ymj.2018.59.4.511.

17.

Mathematical model of viral kinetics in vitro estimates the number of E2-CD81 complexes necessary for hepatitis C virus entry.

Padmanabhan P, Dixit NM.

PLoS Comput Biol. 2011 Dec;7(12):e1002307. doi: 10.1371/journal.pcbi.1002307. Epub 2011 Dec 8.

18.

Identification of conserved residues in hepatitis C virus envelope glycoprotein E2 that modulate virus dependence on CD81 and SRB1 entry factors.

Lavie M, Sarrazin S, Montserret R, Descamps V, Baumert TF, Duverlie G, Séron K, Penin F, Dubuisson J.

J Virol. 2014 Sep;88(18):10584-97. doi: 10.1128/JVI.01402-14. Epub 2014 Jul 2.

19.

CD81 expression is important for the permissiveness of Huh7 cell clones for heterogeneous hepatitis C virus infection.

Akazawa D, Date T, Morikawa K, Murayama A, Miyamoto M, Kaga M, Barth H, Baumert TF, Dubuisson J, Wakita T.

J Virol. 2007 May;81(10):5036-45. Epub 2007 Feb 28.

20.

PCSK9 impedes hepatitis C virus infection in vitro and modulates liver CD81 expression.

Labonté P, Begley S, Guévin C, Asselin MC, Nassoury N, Mayer G, Prat A, Seidah NG.

Hepatology. 2009 Jul;50(1):17-24. doi: 10.1002/hep.22911.

PMID:
19489072

Supplemental Content

Support Center